Literature DB >> 20229159

Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus.

Serdar Farhan1, Thomas Höchtl, Alexandra Kautzky-Willer, Johann Wojta, Kurt Huber.   

Abstract

Diabetes mellitus (DM) is a life-threatening disease. Patients with DM have a 2- to 4-fold higher risk of developing cardiovascular disease compared to their non-diabetic counterparts. Several drugs are available for the treatment of stable coronary artery disease (CAD) and acute coronary syndrome (ACS). Among oral antiplatelet agents (acetylsalicylic acid, ticlopidine, clopidogrel, and prasugrel), prasugrel has shown the highest efficacy in patients with DM and ACS. The use of glycoprotein IIb-IIIa receptor inhibitors in diabetic subjects with ACS undergoing percutaneous coronary intervention (PCI) reduces adverse clinical events in a greater extent than in non-diabetics. Several direct and indirect antithrombins are recommended for the treatment of ACS such as unfractionated heparin (UFH), enoxaparin, fondaparinux, and bivalirudin. Enoxaparin and bivalirudin have been shown to be superior to UFH among patients with ST-elevation MI (STEMI) and non-ST elevation MI (NSTEMI) also in diabetic subgroup analyses.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20229159     DOI： 10.1007/s10354-010-0747-8

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  85 in total

1.  Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.

Authors:  Hitinder S Gurm; Ian J Sarembock; Dean J Kereiakes; John J Young; Robert A Harrington; Neal Kleiman; Frederick Feit; Kathy Wolski; John A Bittl; Robert Wilcox; Eric J Topol; A Michael Lincoff
Journal:  J Am Coll Cardiol       Date:  2005-06-21       Impact factor: 24.094

2.  High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.

Authors:  Kenneth W Mahaffey; Marc Cohen; Jyotsna Garg; Elliott Antman; Neal S Kleiman; Shaun G Goodman; Lisa G Berdan; Craig J Reist; Anatoly Langer; Harvey D White; Philip E Aylward; Jacques J Col; James J Ferguson; Robert M Califf
Journal:  JAMA       Date:  2005-11-23       Impact factor: 56.272

3.  Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans.

Authors:  Michiel E Stegenga; Saskia N van der Crabben; Marcel Levi; Alex F de Vos; Michael W Tanck; Hans P Sauerwein; Tom van der Poll
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

4.  Insulin resistance and human disease: a short history.

Authors:  G M Reaven
Journal:  J Basic Clin Physiol Pharmacol       Date:  1998

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

6.  Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.

Authors:  Tibor Szük; Mariann Gyöngyösi; Nóra Homorodi; Eva Kristóf; Csaba Király; István F Edes; Andrea Facskó; Noemi Pavo; Gottfried Sodeck; Christoph Strehblow; Serdar Farhan; Gerald Maurer; Dietmar Glogar; Hans Domanovits; Kurt Huber; István Edes
Journal:  Am Heart J       Date:  2007-02       Impact factor: 4.749

7.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Authors:  Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone
Journal:  Lancet       Date:  2009-08-28       Impact factor: 79.321

Review 8.  Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.

Authors:  Arun Natarajan; Azfar G Zaman; Sally M Marshall
Journal:  Diab Vasc Dis Res       Date:  2008-06       Impact factor: 3.291

Review 9.  Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

Authors:  John L Petersen; Kenneth W Mahaffey; Vic Hasselblad; Elliott M Antman; Marc Cohen; Shaun G Goodman; Anatoly Langer; Michael A Blazing; Anne Le-Moigne-Amrani; James A de Lemos; Christopher C Nessel; Robert A Harrington; James J Ferguson; Eugene Braunwald; Robert M Califf
Journal:  JAMA       Date:  2004-07-07       Impact factor: 56.272

10.  Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

Authors:  Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman
Journal:  Circulation       Date:  2008-08-31       Impact factor: 29.690
View more
  5 in total

1.  Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI).

Authors:  Yang Liu; Hengliang Liu; Zhenxuan Hao; Guoying Geng; Qi Chen; Wenjie Han; Kailong Jia; Yuxin Zhou
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Effects of Coronary Arterial Injection of Tirofiban on Diabetes Mellitus Complicated with Acute Myocardial Infarction in the Elderly.

Authors:  Yang Liu; Heng-Liang Liu; Guo-Ying Geng; Ning Ba; Song-Bin Jing; Wei Guo; Zhi-Fang Zhang
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

3.  Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention.

Authors:  Ahmed A Ghonim; Abdalla Mostafa; Ahmed Emara; Alaa S Algazzar; Mohammed A Qutub
Journal:  Cardiovasc J Afr       Date:  2019-06-12       Impact factor: 1.167

4.  Comparison of primary coronary percutaneous coronary intervention between Diabetic Men and Women with acute myocardial infarction.

Authors:  Heng-Liang Liu; Yang Liu; Zhen-Xuan Hao; Guo-Ying Geng; Zhi-Fang Zhang; Song-Bin Jing; Ning Ba; Wei Guo
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

5.  Therapeutic Effects of Triple Antiplatelet Therapy in Elderly Female Patients with Diabetes and Acute Myocardial Infarction.

Authors:  Yang Liu; Yanyan Gao; Hengliang Liu; Qi Chen; Jinrui Ji; Kailong Jia
Journal:  Arq Bras Cardiol       Date:  2021-02       Impact factor: 2.000
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.